The Advisory Committee on Immunization Practices (ACIP) met on August 13, 2021 to consider additional doses of COVID-19 vaccines for immunocompromised individuals. ACIP unanimously voted that an additional dose of the Pfizer/BioNTech COVID-19 vaccine (≥12 years) and Moderna COVID-19 vaccine (≥18 years) is recommended following a primary series in immunocompromised people.
Once the ACIP recommendation is approved by the Director of the Centers for Disease Control (CDC), eligible members and dependents will be able to receive the additional doses at no cost.
